Helene Hartvedt Grytli first author on article printed in European Urology and mentioned in The Oncology Report
Helene Hartvedt Grytli from Kristin A. Taskén's "Group of Urological Molecular Biology" at the Department of Tumor Biology is first author on a paper entitled "Association Between Use of β-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease" published in the prestigious journal European Urology (journal impact factor 10.5) (print version March 2014).
The findings have been given special attention through an article in "The Oncology Report", under the headline "Beta-blockers linked to lower mortality in high-risk prostate cancer".
Links:
Association Between Use of β-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease.
Grytli HH, Fagerland MW, Fosså SD, Taskén KA.
Eur Urol. 2014 Mar;65(3):635-41. doi: 10.1016/j.eururo.2013.01.007. Epub 2013 Jan 14.
Mention of the findings in The Oncology Report:
Beta-blockers linked to lower mortality in high-risk prostate cancer
Kristin A. Taskén's Group of Urological Molecular Biology
Deparment of Tumor Biology
Institute for Cancer Research
Previous articles about the research project:
«Prostate Cancers get nerved up», Cancer Discovery, July 25, 2013; doi: 10.1158/2159-8290.